Long non-coding RNAs in non-small cell lung cancer: implications for preventing therapeutic resistance

Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):188982. doi: 10.1016/j.bbcan.2023.188982. Epub 2023 Sep 19.

Abstract

Lung cancer has the highest mortality and morbidity rates among all cancers worldwide. Despite many complex treatment options, including radiotherapy, chemotherapy, targeted drugs, immunotherapy, and combinations of these treatments, efficacy is low in cases of resistance to therapy, metastasis, and advanced disease, contributing to low overall survival. There is a pressing need for the discovery of novel biomarkers and therapeutic targets for the early diagnosis of lung cancer and to determine the efficacy and outcomes of drug treatments. There is now substantial evidence for the diagnostic and prognostic value of long noncoding RNAs (lncRNAs). This review briefly discusses recent findings on the roles and mechanisms of action of lncRNAs in the responses to therapy in non-small cell lung cancer.

Keywords: Angiogenesis; Drug resistance; Immunotherapy resistance; Long noncoding RNA; Non-small cell lung cancer; Radioresistance.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Drug Resistance, Neoplasm / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • RNA, Long Noncoding* / genetics

Substances

  • RNA, Long Noncoding
  • Biomarkers, Tumor